Vericiguat (VERQUVO)
Criteria for Use
June 2021

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

Exclusion Criteria

If the answer to ANY item below is met, the patient should NOT receive vericiguat.

- ☐ Symptomatic hypotension ^1
- ☐ Concomitant use of other soluble guanylate cyclase stimulators (e.g., riociguat)
- ☐ Concomitant use of a PDE-5 inhibitor
- ☐ Pregnancy (i.e., known pregnancy or positive pregnancy test)

Inclusion Criteria

The answers to ALL of the following must be fulfilled in order to meet criteria for patients to be eligible for vericiguat.

- ☐ Restricted to VA / VA Community Care cardiology provider or locally designated expert in the management of heart failure
- ☐ Left ventricular ejection fraction less than 45% with New York Heart Association class II-IV heart failure symptoms
- ☐ Recent evidence of worsening heart failure ^2
- ☐ On guideline directed therapy for heart failure with an ACEI, ARB or ARNI ^3; a beta-blocker; and a mineralocorticoid receptor antagonist (or unable to use these agents)
- ☐ Female patients of child-bearing potential: provided counseling on contraception and potential risks vs. benefits of treatment

1. Use caution in patients at risk for hypotension; patients with systolic blood pressure less than 100 mm Hg were excluded from participation in the pivotal clinical trial
2. e.g., hospitalization for heart failure within the past 6 months despite optimal medical therapy at that time or having received outpatient intravenous diuretic therapy within the previous 3 months as per the inclusion criteria of the pivotal trial
3. ACEI=angiotensin-converting enzyme inhibitor, ARB=angiotensin receptor blocker, ARNI=angiotensin receptor-neprilysin inhibitor